IDYA

IDEAYA Biosciences Inc

Add to Watchlist

Advanced Chart

24.500

-0.33(-1.329%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

24.890

Open

24.670

VWAP

Vol

883.55K

Mkt Cap

2.15B

Low

24.230

Amount

EV/EBITDA(TTM)

Total Shares

75.69M

1.45B

EV/OCF(TTM)

P/S(TTM)

297.40

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.804

+18.17%

-0.809

+34.84%

-0.819

-45.04%

Estimates Revision

The market is revising Downward the revenue expectations for IDEAYA Biosciences, Inc. (IDYA) for FY2025, with the revenue forecasts being adjusted by -13.09% over the past three months. During the same period, the stock price has changed by 24.05%.

Revenue Estimates for FY2025

Revise Downward

-13.09%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+13.93%

In Past 3 Month

Stock Price

Go Up

+24.05%

In Past 3 Month

8 Analyst Rating

72.98% Upside

Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 42.38 USD with a low forecast of 25.00 USD and a high forecast of 66.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

2 Hold

0 Sell

Strong Buy

72.98% Upside

Current: 24.500

Low

25.00

Averages

42.38

High

66.00

72.98% Upside

Current: 24.500

Low

25.00

Averages

42.38

High

66.00

TD Cowen

Tyler Van Buren

Buy

initiated

2025-07-22

Reason

TD Cowen

Tyler Van Buren

Price Target

2025-07-22

initiated

Buy

Reason

TD Cowen analyst Tyler Van Buren initiated coverage of Ideaya Biosciences with a Buy rating and no price target. The company's pipeline, which will soon have nine clinical-stage programs , represents the best of targeted oncology, the analyst tells investors in a research note. The firm believes Ideaya's lead combination drug candidate of darovasertib plus crizotinib should launch in 2026 in metastatic uveal melanoma with a high likelihood of success in neoadjuvant.

Goldman Sachs

Neutral

initiated

$25

2025-07-10

Reason

Goldman Sachs

Price Target

$25

2025-07-10

initiated

Neutral

Reason

Goldman Sachs resumed coverage of Ideaya Biosciences with a Neutral rating and $25 price target. The firm views 2025 as an execution year for the company.

RBC Capital

Gregory Renza

Outperform

NULL

downgrade

$57 -> $30

2025-07-09

Reason

RBC Capital

Gregory Renza

Price Target

$57 -> $30

2025-07-09

downgrade

Outperform

NULL

Reason

RBC Capital analyst Gregory Renza lowered the firm's price target on Ideaya Biosciences to $30 from $57 and keeps an Outperform rating on the shares. The stock has been largely rangebound this year, with less investor attention, but entering the second half, Ideaya should garner more attention given a major Phase 3 event for lead drug daro, as well as a number of supporting pipeline updates, the analyst tells investors in a research note. There's a 65% or more likelihood of success for the phase III readout in metastatic uveal melanoma coming towards year-end, and the firm also sees 40% upside given potential for a rapid launch by 2026, RBC added.

Wells Fargo

Overweight

initiated

$44

2025-06-26

Reason

Wells Fargo

Price Target

$44

2025-06-26

initiated

Overweight

Reason

Stephens & Co.

Sudan Loganathan

Buy

Reiterates

$50

2025-02-14

Reason

Stephens & Co.

Sudan Loganathan

Price Target

$50

2025-02-14

Reiterates

Buy

Reason

RBC Capital

Gregory Renza

Buy

Reiterates

$61

2025-01-15

Reason

RBC Capital

Gregory Renza

Price Target

$61

2025-01-15

Reiterates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for IDEAYA Biosciences Inc (IDYA.O) is -7.59, compared to its 5-year average forward P/E of -9.55. For a more detailed relative valuation and DCF analysis to assess IDEAYA Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.55

Current PE

-7.59

Overvalued PE

5.41

Undervalued PE

-24.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-9.74

Current EV/EBITDA

-3.68

Overvalued EV/EBITDA

10.64

Undervalued EV/EBITDA

-30.12

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

83.13

Current PS

118.42

Overvalued PS

179.25

Undervalued PS

-12.98

Financials

Annual

Quarterly

FY2025Q1

0.00

Total Revenue

FY2025Q1

YoY :

+65.41%

-84.39M

Operating Profit

FY2025Q1

YoY :

+82.40%

-72.18M

Net Income after Tax

FY2025Q1

YoY :

+54.72%

-0.82

EPS - Diluted

FY2025Q1

YoY :

+36.63%

-61.67M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

YoY :

+340.18%

-3.83K

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

85.8K

Volume

6-9

Months

1.3M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.7M

Volume

Months

6-9

1.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IDYA News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

14:14:54

Oncology stocks 'bearing the brunt' of Prasad news, says Oppenheimer

2025-05-06

06:42:52

Ideaya Biosciences announces FDA clearance for IDE849

2025-05-06

06:11:01

Ideaya Biosciences reports Q1 EPS (82c), consensus (69c)

News

9.0

07-24Newsfilter

IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma

2.0

07-23NASDAQ.COM

Bullish Two Hundred Day Moving Average Cross - IDYA

1.0

07-23PRnewswire

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy